Everything below concerns NR1D1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
=== Semi-rational design === Semi-rational design is a purposeful modification method based on a certain understanding of the sequence, structure, and catalytic mechanism of enzymes. This method is between irrational design and rational design. It uses known information and means to perform evolutionary modification on the specific functions of the target enzyme. The characteristic of semi-rational design is that it does not rely solely on random mutation and screening, but combines the concept of directed evolution. It creates a library of random mutants with diverse sequences through mutagenesis, error-prone RCR, DNA recombination, and site-saturation mutagenesis. At the same time, it uses the understanding of enzymes and design principles to purposefully screen out mutants with desired characteristics. The methodology of semi-rational design emphasizes the in-depth understanding of enzymes and the control of the evolutionary process. It allows researchers to use known information to guide the evolutionary process, thereby improving efficiency and success rate. This method plays an important role in protein function modification because it can combine the advantages of irrational design and rational design, and can explore unknown space and use known knowledge for targeted modification. Semi-rational design has a wide range of applications, including but not limited to enzyme optimization, modification of drug targets, evolution of biocatalysts, etc.
In 2019, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that product labels for all SSRIs and SNRIs, including sertraline, be updated to state that sexual dysfunction may be long-lasting even after treatment is stopped. Health Canada followed with similar label updates in 2021. In 2024, Australia's Therapeutic Goods Administration aligned all SSRI and SNRI product information to reflect this risk, noting that sertraline already carried a warning about persistent sexual dysfunction.
== Medical uses == Olipudase alfa is indicated as an enzyme replacement therapy for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency in people with type A/B or type B. Olipudase alfa is an enzyme replacement therapy, developed to replace patients' deficient or defective enzyme, acid sphingomyelinase, and thereby reduce fat accumulation within cells and relieve some of the symptoms of the disease. Xenpozyme was approved by the European Medicines Agency for the treatment of acid sphingomyelinase deficiency type A/B or type B, and by the US FDA for the treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency.
Sources: en.wikipedia.org
=== Purine metabolism === GMP synthase is the second step in the generation of GMP from IMP; the first step occurs when IMP dehydrogenase generates XMP, and then GMP synthetase is able to react with glutamine and ATP to generate GMP. IMP may also be generated into AMP by adenylosuccinate synthetase and then adenylosuccinate lyase.
This multidisciplinary approach allows researchers to identify vulnerable populations, characterize disparities in dementia incidence and outcomes, and evaluate interventions that may delay cognitive decline and improve quality of life for aging individuals. A defining strength of CAPAS is its emphasis on health equity and the study of historically underrepresented populations. Investigators examine racial, ethnic, geographic, and socioeconomic disparities in dementia risk, diagnosis, treatment, caregiving, and healthcare utilization, with particular attention to Hispanic, rural, and medically underserved communities throughout South Texas and the United States. By investigating the social determinants of brain health alongside biological mechanisms of aging, the Center provides critical insights into why dementia disproportionately affects certain populations and identifies opportunities to reduce inequities through targeted prevention strategies, public health initiatives, and healthcare policy. The Center also serves as an important resource for methodological innovation in population aging research. Faculty develop and apply advanced analytical approaches—including longitudinal data analysis, causal inference methods, machine learning, geospatial analysis, and health services research—to better understand the complex interactions among aging, chronic disease, cognitive decline, and social determinants of health.
=== ESI variations === There are some ESI methods that require little to no sample preparation. One such method is a method termed extractive electrospray ionization (EESI). This method involves having an electrospray of solvent directed at an angle against a different spray of the sample solution, produced by a separate nebulizer. This method requires no sample preparation in that the electrospray of solvent extracts the sample from the complex mixture, effectively removing any background contaminants. Another particularly powerful variation on ESI is desorption electrospray ionization (DESI), which involves directing an electrospray at a surface with the sample deposited on top of it. The sample is ionized in the electrospray as it splashes off the surface, then traveling to the mass spectrometer. This method is important because no sample preparation is needed for this method. A sample simply needs to be deposited on a surface, such as paper. Atmospheric pressure chemical ionization (APCI) is similar to ESI in that the sample is nebulized in droplets that are then evaporated, leaving behind a charged ion to be analyzed. APCI experiences few of the negative matrix effects experienced by ESI due to the fact that ionization occurs in the gas phase in this method rather than the within the liquid droplets as in ESI and the fact that in APCI there is an overabundance of reaction gas, thus minimizing the effect of the matrix on the ionization process.
As part of a comprehensive modernization of German radiation protection law, which is largely based on Directive 2013/59/Euratom, the provisions of the X-Ray Ordinance have been incorporated into the revised Radiation Protection Ordinance. Among many other measures, contaminated food was withdrawn from the market on a large scale. Parents were strongly advised not to let their children play in sandboxes. Some of the contaminated sand was replaced. In 1989, the Federal Office for Radiation Protection was incorporated into the Ministry of the Environment. On April 30, 2003, a new precautionary radiation protection law was promulgated to implement two EU directives on the health protection of persons against the dangers of ionizing radiation during medical exposure. The protection of workers from optical radiation (infrared radiation (IR), visible light (VIS) and ultraviolet radiation (UV)), which falls under the category of non-ionizing radiation, is regulated by the Ordinance on the Protection of Workers from Artificial Optical Radiation of 19 July 2010. It is based on the EU Directive 2006/25/EC of April 27, 2006. On March 1, 2010, the "Act on the Protection of Humans from Non-Ionizing Radiation" (NiSG), BGBl. I p. 2433, came into force, according to which the use of sunbeds by minors has been prohibited since August 4, 2009, in accordance with § 4 NiSG [Network and Information Systems Security Ordinance – NIS Ordinance] (in German) A new Radiation Protection Act came into force in Germany on October 1, 2017.
Sources: en.wikipedia.org
Ability to determine the origin of a product, ingredient or component. Simplifies problem-solving in event of defective or contaminated product, ingredient or component. Allows issues to be more quickly identified, contained and resolved. Limits losses and lowers costs. Protects public health and safety. Builds trust and confidence in affected products, businesses or systems. Verifies that produce is locally grown. Improves operating efficiencies for growers, packers and shippers.
The Canadian Armed Forces provides each soldier with a complete pre-cooked meal known as the Individual Meal Pack (IMP), packaged inside a heavy-duty folding paper bag. There are 5 breakfast menus, 6 lunch menus, and 6 supper menus. Canadian rations provide generous portions and contain a large number of commercially available items. The main meal is precooked and ready-to-eat, packed in heavy-duty plastic-foil retort pouches boxed with cardboard. Typically, the ration contains a meal item (beans and wiener sausages, scalloped potatoes with ham, smoked salmon fillet, macaroni and cheese, cheese omelette with mushrooms, shepherd's pie, etc.), wet-packed (sliced or mashed) fruit in a boxed retort pouch, and depending on the meal a combination of instant soup or cereal, fruit drink crystals, jam or cheese spread, peanut butter, honey, crackers, bread (bun) compressed into a retort pouch, coffee and tea, sugar, commercially available chocolate bars and hard candy, a long plastic spoon, paper towels and wet wipes. Canada also makes limited use of a Light Meal Pack containing dried meat or cheese, dried fruit, a granola bar, a breakfast cereal square, a chocolate bar, hard candy, hot cocoa mix, tea, and two pouches of instant fruit drink. Canadian ration packs also contain a book of cardboard matches.
Social well-being concerns the quality and number of interpersonal connections, including how well a person functions in their social environment and the level of social support available to them. Economic well-being refers to the economic situation of a person, such as their current employment situation, job opportunities, financial stability, and other relevant resources and skills. Further types of well-being include financial, cultural, political, and environmental well-being.
== Effects == T3 increases the basal metabolic rate and, thus, increases the body's oxygen and energy consumption. The basal metabolic rate is the minimal caloric requirement needed to sustain life in a resting individual. T3 acts on the majority of tissues within the body, with a few exceptions including the spleen. It increases the synthesis and activity of the Na+/K+-ATPase (which normally constitutes a substantial fraction of total cellular ATP expenditure) without disrupting transmembrane ion balance. In general, it increases the turnover of different endogenous macromolecules by increasing their synthesis and degradation.
=== Affinity chromatography === Affinity chromatography emerged in the 1950s as a rarely used method used to purify enzymes; it has since seen mainstream use and is the oldest among chemoproteomic approaches. Affinity chromatography is performed following one of two basic formats: ligand immobilization or target immobilization. Under the ligand immobilization format, a ligand of interest - often a drug lead - is immobilized within a chromatography column and acts as the stationary phase. A complex sample consisting of many proteins, such as a cell lysate, is passed through the column and the target of interest binds to the immobilized ligand while other sample components pass through the column unretained. Under the target immobilization format, a target of interest - often a disease-relevant protein - is immobilized within a chromatography column and acts as the stationary phase. Pooled compound libraries are then passed through the column in an application buffer, ligands are retained through binding interactions with the stationary phase, and other compounds pass through the column unretained. In both cases, retained analytes can be eluted from the column and identified using mass spectrometry. A table of elution strategies is provided below.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.